The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure: The ASTRONAUT Randomized Trial
Open accessAbstract
IMPORTANCE: Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality. OBJECTIVE: To investigate whether aliskiren, a direct renin inhibitor, when added to standard therapy, would reduce the rate of cardiovascular (CV) death or HF rehospitalization among HHF patients. DESIGN, SETTING, AND PARTICIPANTS: International, double-blind, placebo-controlled study that randomized hemodynamically stable HHF patients a median 5 days after admission. Eligible patients were 18 years or older with left ventricular ejection fraction (LVEF) 40% or less, elevated natriuretic peptides (brain natriuretic peptide [BNP] ≥ 400 pg/mL or N -terminal pro-BNP [NT-proBNP] ≥ 1600 pg/mL), and signs and symptoms of fluid overload. Patients were recruited from 316 sites across North and South America, Europe, and Asia between May 2009 and December 2011. The follow-up period ended in July 2012. INTERVENTION: All patients received 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months. MAIN OUTCOME MEASURES Cardiovascular death or HF rehospitalization at 6 months and 12 months. RESULTS: In total, 1639 patients were randomized, with 1615 patients included in the final efficacy analysis cohort (808 aliskiren, 807 placebo). Mean age was 65 years; mean LVEF, 28%; 41% of patients had diabetes mellitus, mean estimated glomerular filtration rate, 67 mL/min/1.73 m2. At admission and randomization, median NT-proBNP levels were 4239 pg/mL and 2718 pg/mL, respectively. At randomization, patients were receiving diuretics (95.9%), β-blockers (82.5%), angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (84.2%), and mineralocorticoid receptor antagonists (57.0%). In total, 24.9% of patients receiving aliskiren (77 CV deaths, 153 HF rehospitalizations) and 26.5% of patients receiving placebo (85 CV deaths, 166 HF rehospitalizations) experienced the primary end point at 6 months (hazard ratio [HR], 0.92; 95% CI, 0.76-1.12; P = .41). At 12 months, the event rates were 35.0% for the aliskiren group (126 CV deaths, 212 HF rehospitalizations) and 37.3% for the placebo group (137 CV deaths, 224 HF rehospitalizations; HR, 0.93; 95% CI, 0.79-1.09; P = .36). The rates of hyperkalemia, hypotension, and renal impairment/renal failure were higher in the aliskiren group compared with placebo. CONCLUSION AND RELEVANCE: Among patients hospitalized for HF with reduced LVEF, initiation of aliskiren in addition to standard therapy did not reduce CV death or HF rehospitalization at 6 months or 12 months after discharge. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00894387.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Self-citationSwedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationMcMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563 · cited 1×
“Moreover, given the persistently high postdischarge event rate confirmed in ASTRONAUT, future HF trials are encouraged to prioritize study of this population over outpatients with chronic HF who have a lower event rate.(27)”
Self-citationKonstam, M. A. (2007) · JAMA · doi:10.1001/jama.297.12.1319 · Cited by 1,628
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“Although the diabetes subgroup findings are intriguing, they must be interpreted with caution because of the wellknown statistical limitations (ie, low number of patients by subgroup, multiplicity adjustment).(26) This may be particularly relevant in the specific case of ASTRONAUT, in which the observed findings were…”
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Self-citationMcMurray, J. J. V., Östergren, J., Swedberg, K. B., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer (2003) · The Lancet · Cited by 1,043
Gheorghiade, M., Abraham, W. T., Albert, N. M., Greenberg, B. H., O’Connor, C. M., She, L., Stough, W. G., Yancy, C. W., Young, J. B., Fonarow, G. C., et al. (2006) · JAMA · doi:10.1001/jama.296.18.2217 · Cited by 975
Self-citationRehospitalization for Heart Failure
Gheorghiade, M., Vaduganathan, M., Fonarow, G. C., & Bonow, R. O. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.038 · Cited by 730
Self-citationEffects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
McMurray, J. J. V., Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Keefe, D. L., Ford, J., Verma, A., & Lewsey, J. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.107.740704 · Cited by 358
Self-citationRacial Differences in Blood Pressure Control: Potential Explanatory Factors
Bosworth, H. B., Dudley, T., Olsen, M. K., Voils, C. I., Powers, B., Goldstein, M. K., & Oddone, E. Z. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.019 · Cited by 276
Harjola, V.-P., Follath, F., Nieminen, M. S., Brutsaert, D., Dickstein, K., Drexler, H., Hochadel, M., Komajda, M., Lopez-Sendon, J. L., Ponikowski, P., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq002 · Cited by 244
Sarma, S., Mentz, R. J., Kwasny, M. J., Fought, A. J., Huffman, M., Subacius, H., Nodari, S., Konstam, M., Swedberg, K., Maggioni, A. P., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs153 · Cited by 202 · cited 1×
“However, irrespective of mechanism, the influence of baseline DM on event rate further highlights the heterogeneity of clinical profiles seen in HHF and suggests a role for further patient stratification in future studies.(23,24) The ongoing long-term Aliskiren Trial of Minimizing Outcomes in Patients with Heart Failu…”
Blair, J. E. A., Zannad, F., Konstam, M. A., Cook, T., Traver, B., Burnett, J. C., Grinfeld, L., Krasa, H., Maggioni, A. P., Orlandi, C., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.056 · Cited by 173
Self-citationGheorghiade, M., Orlandi, C., Burnett, J. C., DeMets, D., Grinfeld, L., Maggioni, A., Swedberg, K., Udelson, J. E., Zannad, F., Zimmer, C., et al. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.03.009 · Cited by 171
Self-citationRenal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans
Fisher, N. D. L., Jan Danser, A. H., Nussberger, J., Dole, W. P., & Hollenberg, N. K. (2008) · Circulation · doi:10.1161/circulationaha.108.767202 · Cited by 163
Felker, G. M., Pang, P. S., Adams, K. F., Cleland, J. G. F., Cotter, G., Dickstein, K., Filippatos, G. S., Fonarow, G. C., Greenberg, B., Hernandez, A. F., et al. (2010) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.893222 · Cited by 154
Self-citationKrum, H., Massie, B. M., Abraham, W. T., Dickstein, K., Køber, L., McMurray, J. J. V., Desai, A., Gimpelewicz, C. R., Kandra, A., Reimund, B., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq212 · Cited by 142
Self-citationSchmieder, R. E., Philipp, T., Guerediaga, J., Gorostidi, M., Smith, B. A., Weissbach, N., Maboudian, M., Botha, J., & van Ingen, H. (2009) · Circulation · doi:10.1161/circulationaha.107.750745 · Cited by 141
Self-citationGheorghiade, M., Pang, P. S., Ambrosy, A. P., Lan, G., Schmidt, P. H., Filippatos, G. S., Konstam, M. A., Swedberg, K. B., Cook, T. D., Traver, B., et al. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9280-0 · Cited by 125
Self-citationIncremental Prognostic Value of Changes in B-Type Natriuretic Peptide in Heart Failure
Latini, R., Masson, S., Wong, M., Barlera, S., Carretta, E., Staszewsky, L. I., Vago, T., Maggioni, A. P., Anand, I. S., Tan, L. B., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.041 · Cited by 118
Self-citationGheorghiade, M., Albaghdadi, M. S., Zannad, F. M., Fonarow, G. C., Böhm, M., Gimpelewicz, C. R., Botha, J., Moores, S. L., Lewis, E. F., Rattunde, H., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq209 · Cited by 84
Self-citationNeurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials
Gheorghiade, M., Luca, L. D., & Bonow, R. O. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.059 · Cited by 32
Self-citation
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Self-citation(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citation
Metadata
- Authors
- Gheorghiade, M., Böhm, M., Greene, S. J., Fonarow, G. C., Lewis, E. F., Zannad, F., Solomon, S. D., Baschiera, F., Botha, J., Hua, T. A., Gimpelewicz, C. R., Jaumont, X., Lesogor, A., Maggioni, A. P., & ASTRONAUT Investigators and Coordinators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-03-20
- Volume
- 309
- Issue
- 11
- Pages
- 1125
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2168507847
- Cited by
- 328
- References
- 32
- FWCI
- 38.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.